Condition: Ovarian Cancer · Sponsor: NX Development Corp
This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study participation lasting about two (2) weeks.
This description comes directly from the study's public registry record.
Michael Giammona · 512-348-3885 · mgiammona@nxdevcorp.com
Ron Mims · 505-681-3537 · rmims@nxdevcorp.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic Florida | Jacksonville, Florida, United States | Recruiting |
| Luminis Health Anne Arundel Medical Center | Annapolis, Maryland, United States | Completed |
| University of Maryland | Baltimore, Maryland, United States | Recruiting |
| Mayo Clinic Methodist Campus | Rochester, Minnesota, United States | Recruiting |
| Mount Sinai | New York, New York, United States | Recruiting |
| The Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| WellSpan Health | York, Pennsylvania, United States | Recruiting |
| Riverside Health | Newport News, Virginia, United States | Recruiting |
| CAMC Institute for Academic Medicine - Cancer Research Center | Charleston, West Virginia, United States | Recruiting |
| WVU Cancer Institute | Morgantown, West Virginia, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05804370